PE20231554A1 - Composiciones y procedimientos utiles para la prevencion y/o el tratamiento de enfermedades en mamiferos - Google Patents

Composiciones y procedimientos utiles para la prevencion y/o el tratamiento de enfermedades en mamiferos

Info

Publication number
PE20231554A1
PE20231554A1 PE2022003070A PE2022003070A PE20231554A1 PE 20231554 A1 PE20231554 A1 PE 20231554A1 PE 2022003070 A PE2022003070 A PE 2022003070A PE 2022003070 A PE2022003070 A PE 2022003070A PE 20231554 A1 PE20231554 A1 PE 20231554A1
Authority
PE
Peru
Prior art keywords
kda
diseases
mammals
prevention
compositions
Prior art date
Application number
PE2022003070A
Other languages
English (en)
Spanish (es)
Inventor
Michelle Olga Patricia Giesteira Da Silva Smit
Original Assignee
Viro Gen Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viro Gen Pty Ltd filed Critical Viro Gen Pty Ltd
Publication of PE20231554A1 publication Critical patent/PE20231554A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001132—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2022003070A 2020-07-09 2021-07-09 Composiciones y procedimientos utiles para la prevencion y/o el tratamiento de enfermedades en mamiferos PE20231554A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ZA202003850 2020-07-09
ZA202004008 2020-07-09
PCT/IB2021/056179 WO2022009165A1 (en) 2020-07-09 2021-07-09 Compositions and methods useful for the prevention and/or treatment of disease in mammals

Publications (1)

Publication Number Publication Date
PE20231554A1 true PE20231554A1 (es) 2023-10-03

Family

ID=79552952

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022003070A PE20231554A1 (es) 2020-07-09 2021-07-09 Composiciones y procedimientos utiles para la prevencion y/o el tratamiento de enfermedades en mamiferos

Country Status (16)

Country Link
US (1) US20240091310A1 (OSRAM)
EP (1) EP4178604A4 (OSRAM)
JP (1) JP2023533162A (OSRAM)
KR (1) KR20230038230A (OSRAM)
CN (1) CN115720520A (OSRAM)
AU (1) AU2021304479A1 (OSRAM)
BR (1) BR112022026874A2 (OSRAM)
CA (1) CA3179965A1 (OSRAM)
CL (1) CL2023000073A1 (OSRAM)
CO (1) CO2022019251A2 (OSRAM)
IL (1) IL299661A (OSRAM)
MX (1) MX2023000113A (OSRAM)
PE (1) PE20231554A1 (OSRAM)
PH (1) PH12023550038A1 (OSRAM)
WO (1) WO2022009165A1 (OSRAM)
ZA (1) ZA202213371B (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025215561A1 (en) * 2024-04-09 2025-10-16 Viro-Gen (Pty) Ltd Plasmid for expression of ksp37
WO2025221871A1 (en) * 2024-04-16 2025-10-23 The Trustees Of Columbia University In The City Of New York Expansion, propagation, and modulation of immune cell subsets by peptides
WO2025233869A1 (en) * 2024-05-07 2025-11-13 Viro-Gen (Pty) Ltd Compounds, compositions and methods for treating, reversing or preventing type 2 diabetes mellitus
WO2025233868A1 (en) * 2024-05-07 2025-11-13 Viro-Gen (Pty) Ltd Compounds, compositions and methods for treating, reversing or preventing cancer

Also Published As

Publication number Publication date
JP2023533162A (ja) 2023-08-02
ZA202213371B (en) 2023-11-29
PH12023550038A1 (en) 2024-03-11
MX2023000113A (es) 2023-03-16
CL2023000073A1 (es) 2023-07-07
KR20230038230A (ko) 2023-03-17
AU2021304479A1 (en) 2023-01-19
EP4178604A1 (en) 2023-05-17
EP4178604A4 (en) 2024-07-31
BR112022026874A2 (pt) 2023-01-24
IL299661A (en) 2023-03-01
CO2022019251A2 (es) 2023-03-27
WO2022009165A1 (en) 2022-01-13
CN115720520A (zh) 2023-02-28
US20240091310A1 (en) 2024-03-21
CA3179965A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
CO2022019251A2 (es) Composiciones y métodos útiles para la prevención y/o el tratamiento de enfermedades en mamíferos
MX2023001466A (es) Enlazadores de base peptidica.
MX2023014059A (es) Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante.
CY1114716T1 (el) Ανασυσταθεντα επιφανειοδραστικα τα οποια διαθετουν βελτιωμενες ιδιοτητες
MX391339B (es) Composicion farmaceutica que comprende selexipag.
JOP20250030A1 (ar) متقارنات وبروتينات ربط مستقبل الترانسفيرين
MX2020010701A (es) Péptidos antigénicos para la prevención y el tratamiento del cáncer.
AR108631A1 (es) Formulación de neurotoxinas
BR112019009133A2 (pt) vacina contra o parvovírus suíno
SA520420287B1 (ar) مركبات مساعدة لعامل تمايز النمو 15 وطرق استخدامها
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
BR112021021213A2 (pt) Administração heteróloga de vacinas de tau
JOP20220259A1 (ar) تركيبات تشتمل على جسيمات نانونية، طريقة تصنيعها واستخدامها
EA202091690A1 (ru) Иммуногенная композиция, содержащая стафилококковые антигены
CL2024000062A1 (es) Composición farmacéutica de virus no encapsulado
BR112022014844A2 (pt) Tratamento de doenças associadas ao panx1
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
MX2023009921A (es) Formulaciones de proteinas de fusion ace2-fc.
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
MX2022012165A (es) Interaccion de proteinas de sars-cov-2 con mecanismos moleculares y celulares de celulas huespedes y formulaciones para tratar covid-19.
BR112023019795A2 (pt) Composições nasais compreendendo alcaftadina
BR112020004935A2 (pt) Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular
BR112023011605A2 (pt) Uso do peptídeo, método de tratamento de câncer ou infecções virais, e, combinação farmacêutica
ZA202401042B (en) Protein compositions for the treatment of inflammatory diseases
BR112017022390A2 (pt) composição farmacêutica